Deutsche medizinische Wochenschrift
-
5-year survival data from the KEYNOTE-024 trial confirm the sustained efficacy of immuno-oncologic monotherapy in patients with NSCLC with high PD-L1 expression (≥ 50 %). DUAL IMMUNOTHERAPY IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE THERAPY FOR NSCLC: Nivolumab plus impilimumab in combination with 2 cycles of platinum-containing chemotherapy improves survival in NSCLC patients. ⋯ The nationwide network nNGM provides NSCLC patients with access to state-of-the-art molecular diagnostics and the latest treatment options.
-
The article presents an organizational structure for the psycho-oncological treatment of cancer patients that is unique in Germany, in which professional therapeutic support is provided by practioners from a wide range of professions "under one roof". In addition, from the perspective of a psychooncologist, the intra-psychic processes that cancer patients can go through during their illness are described, as well as their psychooncological-psychotherapeutic treatment. ⋯ In conclusion, it is stated that psychooncology in its best sense can help patients to recognize the value of their lives and, regardless of the time span left to live, to make life worth living. This claim requires for the psychooncological approach a holistic therapy offer, which also includes existential and trauma-oriented dimensions in the treatment.
-
Pain history should be adapted to their cognitive abilities of people with dementia who can still communicate. With increasing limitations of communication skills, history of a third party and standardized observation instruments increase in importance. ⋯ Opioids and coanalgetics have hardly been studied in this group although frequently used. Anticholinergic side effects are especially important in people with dementia.